The clinical trial investigates the efficacy of Januvia (sitagliptin) in reducing inflammation and improving endothelial function in HIV-infected individuals with insulin resistance and cardiovascular disease risk factors. Given the high prevalence of diabetes and cardiovascular complications in this population, successful outcomes could position sitagliptin as a novel therapeutic option, expanding its market beyond diabetes management to include HIV-related cardiometabolic complications. This could enhance Merck's portfolio and provide a competitive edge in the growing market for treatments addressing comorbidities in HIV patients. Diligence should focus on the regulatory landscape and potential reimbursement pathways for this indication.